Vaxxas announced that it received a $3.67 million award to conduct studies of a typhoid vaccine delivered by its needle-free device.
The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to the skin as a patch, the system rapidly delivers vaccines to immune cells below the skin surface.
HD-MAP offers improved thermostability, potentially reducing the cost and complexity of cold-chain distribution and storage. It also potentially requires less training to administer and could even lead to self-administration.
Get the full story at our sister site, Drug Delivery Business News.